

# Brian M Wolpin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2612367/brian-m-wolpin-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80  
papers

4,688  
citations

32  
h-index

68  
g-index

87  
ext. papers

6,340  
ext. citations

15.1  
avg, IF

4.97  
L-index

#	Paper	IF	Citations
80	Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. <i>Nature</i> , <b>2017</b> , 547, 453-457	50.4	620
79	Systemic treatment of colorectal cancer. <i>Gastroenterology</i> , <b>2008</b> , 134, 1296-310	13.3	364
78	ABO blood group and the risk of pancreatic cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 424-31	9.7	266
77	Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 193-8	2.2	240
76	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , <b>2014</b> , 46, 994-1000	36.3	226
75	Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. <i>Oncologist</i> , <b>2014</b> , 19, 637-8	5.7	220
74	Adjuvant treatment of colorectal cancer. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2007</b> , 57, 168-85	220.7	193
73	Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 176-85	2.2	183
72	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 911-6	36.3	171
71	Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. <i>Cancer Research</i> , <b>2010</b> , 70, 1015-23	10.1	168
70	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1096-1111	24.4	156
69	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , <b>2020</b> , 26, 878-885	50.5	126
68	Hyperglycemia, insulin resistance, impaired pancreatic $\beta$ cell function, and risk of pancreatic cancer. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1027-35	9.7	108
67	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 556	17.4	103
66	Acquired Resistance to KRAS Inhibition in Cancer. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2382-2393	39.2	91
65	Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 82-91	4	81
64	Characterization of large structural genetic mosaicism in human autosomes. <i>American Journal of Human Genetics</i> , <b>2015</b> , 96, 487-97	11	77

63	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6616-33	5.6	77
62	Atypical KRAS Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. <i>Cancer Discovery</i> , <b>2020</b> , 10, 104-123	24.4	70
61	Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 3140-9	4	67
60	Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. <i>PLoS Genetics</i> , <b>2016</b> , 12, e1006493	6	67
59	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. <i>Oncotarget</i> , <b>2016</b> , 7, 66328-66343	3.3	66
58	Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. <i>Cancer Research</i> , <b>2007</b> , 67, 7923-8	10.1	58
57	The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. <i>European Heart Journal</i> , <b>2020</b> , 41, 2645-2656	9.5	54
56	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 800-811	4.3	52
55	Critical role for arginase 2 in obesity-associated pancreatic cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 242	17.4	47
54	TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2175-83	7.5	46
53	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. <i>Cancer Cell</i> , <b>2020</b> , 38, 198-211.e8	24.3	38
52	Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. <i>Oncologist</i> , <b>2013</b> , 18, 377-8	5.7	37
51	Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. <i>Nature Communications</i> , <b>2020</b> , 11, 4296	17.4	37
50	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , <b>2020</b> , 181, 832-847.e18	56.2	34
49	Discovery of a selective inhibitor of doublecortin like kinase 1. <i>Nature Chemical Biology</i> , <b>2020</b> , 16, 635-643	11.7	33
48	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. <i>Nature Communications</i> , <b>2020</b> , 11, 3353	17.4	32
47	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. <i>Cancer Research</i> , <b>2016</b> , 76, 7160-7167	10.1	32
46	Leucocyte telomere length, genetic variants at the gene region and risk of pancreatic cancer. <i>Gut</i> , <b>2017</b> , 66, 1116-1122	19.2	28

45	Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. <i>Nature Communications</i> , <b>2017</b> , 8, 15034	17.4	26
44	Quantifying the Genetic Correlation between Multiple Cancer Types. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2017</b> , 26, 1427-1435	4	25
43	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 1003-1012	9.7	25
42	Low glycaemic diets alter lipid metabolism to influence tumour growth. <i>Nature</i> , <b>2021</b> , 599, 302-307	50.4	24
41	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. <i>Gastroenterology</i> , <b>2021</b> , 160, 1373-1383.e6	13.3	23
40	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 1185-91	4	22
39	Population-Scale CT-based Body Composition Analysis of a Large Outpatient Population Using Deep Learning to Derive Age-, Sex-, and Race-specific Reference Curves. <i>Radiology</i> , <b>2021</b> , 298, 319-329	20.5	22
38	Covariate selection for association screening in multiphenotype genetic studies. <i>Nature Genetics</i> , <b>2017</b> , 49, 1789-1795	36.3	19
37	Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on DIS3 expression. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 4726-4738	5.6	17
36	Characterising -regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. <i>Gut</i> , <b>2018</b> , 67, 521-533	19.2	16
35	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2014-2031	24.4	16
34	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 557-567	9.7	16
33	Circulating Exosomes in Pancreatic Cancer: Will They Succeed on the Long, Littered Road to Early Detection Marker?. <i>Clinical Chemistry</i> , <b>2016</b> , 62, 307-9	5.5	15
32	Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 208-13	3.8	15
31	Variants associated with susceptibility to pancreatic cancer and melanoma do not reciprocally affect risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 1121-4	4	14
30	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. <i>Cell</i> , <b>2021</b> , 184, 6119-6137.e26	56.2	13
29	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 170-179	9.7	11
28	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4574-4586	12.9	11

27	When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 485-489	2.2	8
26	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , <b>2015</b> , 29, 761-76	3.1	8
25	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 999-1008	4	7
24	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. <i>Cell Reports</i> , <b>2020</b> , 33, 108493	10.6	7
23	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. <i>Genome Medicine</i> , <b>2021</b> , 13, 15	14.4	6
22	A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1533-1539	4.3	5
21	Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 1784-1791	4	4
20	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. <i>Practical Radiation Oncology</i> , <b>2014</b> , 4, e117-e123	2.8	4
19	Clinical problem-solving. The writing on the wall. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 1387-92	59.2	4
18	Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 596931	5.3	4
17	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. <i>American Journal of Roentgenology</i> , <b>2019</b> , 212, 596-601	5.4	3
16	Retrospective Case Series Analysis of Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	3
15	A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 296-296	2.2	2
14	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 2735-2739	4	2
13	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. <i>American Journal of Clinical Nutrition</i> , <b>2021</b> , 114, 1408-1417	7	2
12	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. <i>Cancer Research</i> , <b>2021</b> , 81, 3134-3143	10.1	2
11	Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3199-3206	2.2	2
10	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. <i>Cancer Research</i> , <b>2020</b> , 80, 4004-4013	10.1	1

9	A phase 1b study evaluating IL-1 $\beta$ and PD-1 targeting with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 557-557	2.2	1
8	Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 10528-10528	2.2	1
7	A 584bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. <i>American Journal of Human Genetics</i> , <b>2021</b> , 108, 1852-1865	11	1
6	G-CSF-induced carotid inflammation.. <i>Lancet Oncology, The</i> , <b>2022</b> , 23, e235	21.7	1
5	Reply to Y. Mao et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2121-2	2.2	
4	Reply to A. Braillon. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1136-1137	2.2	
3	Identification of the Metabolomic Fingerprint Associated with Flavonoid Consumption Level. <i>FASEB Journal</i> , <b>2015</b> , 29, 745.7	0.9	
2	Feasibility of computer-based self-administered cancer-specific geriatric assessment (SA-CSGA) in older pts with gastrointestinal malignancy (GIM).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e19586-e19586	2.2	
1	Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. <i>BMJ Open Sport and Exercise Medicine</i> , <b>2022</b> , 8, e001353	3.4	